Cutaneous and subcutaneous mast cell tumours (MCTs) are counted among the most frequent cancers in dogs. However, the genetic aetiology of their development is still mostly unknown, with the exception of KIT and tumor protein p53 (TP53 ) mutations reported in less than a half of cutaneous MCTs. In subcutaneous MCTs, no gene alterations were previously detected. We analysed KIT and TP53 mutations in cutaneous and subcutaneous MCTs, and identified methylated CpG sites in KIT and TP53 promoters and adjacent exon 1 regions. The mutation analysis focused on KIT exons 8, 9 and 11, and TP53 exons 5-8, and revealed mutations in 26% and 7% cutaneous MCT cases, respectively. Moreover, we report a first case of KIT mutation ever detected in subcutaneous MCTs. KIT exon 11 mutations and high Kiupel and Patnaik grades were associated with reduced survival in this study. Both KIT and TP53 gene were generally unmethylated in canine cutaneous MCTs. A sporadic methylation of the CpG positions in KIT promoter and adjacent exon 1 was detected in 70.4% of cutaneous and 82% of subcutaneous MCTs. A sporadic methylation of the CpG positions in the TP53 promoter and exon 1 was observed in 36.8% of the analysed cutaneous MCT samples. Only in two subcutaneous MCTs, we observed more than 30% of clones showing KIT methylation at the CpG positions 13 or 14. The CpG position 14 is involved in a predicted binding site for Sp1 transcription factor. However, the significance of KIT promoter methylation at this specific position needs further evaluation.

Department of Genetics and Reproduction Central European Institute of Technology Veterinary Research Institute Brno Czech Republic

Department of Pathological Morphology and Parasitology Faculty of Veterinary Medicine University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

See more in PubMed

Sledge DG, Webster J, Kiupel M. Canine cutaneous mast cell tumors: a combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection. Vet J. 2016;215:43-54. https://doi.org/10.1016/j.tvjl.2016.06.003.

Welle MM, Bley CR, Howard J, Rüfenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol. 2008;19:321-339. https://doi.org/10.1111/j.1365-3164.2008.00694.x.

Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984;21:469-474.

Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48:147-155. https://doi.org/10.1177/0300985810386469.

Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia. 2006;8:104-111. https://doi.org/10.1593/neo.05622.

Webster JD, Yuzbasiyan-Gurkan V, Miller RA, et al. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol. 2007;44:298-308. https://doi.org/10.1354/vp.44-3-298.

Giantin M, Vascellari M, Morello EM, et al. C-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. J Vet Diagn Invest. 2012;24:116-126. https://doi.org/10.1177/1040638711425945.

Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res. 2002;63:1718-1723.

Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6:1137-1145. https://doi.org/10.1158/1541-7786.MCR-08-0067.

Takeuchi Y, Fujino Y, Watanabe M, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J. 2013;196:492-498. https://doi.org/10.1016/j.tvjl.2012.11.018.

Vozdova M, Kubickova S, Fictum P, et al. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. Vet J. 2019;247:71-74. https://doi.org/10.1016/j.tvjl.2019.03.005.

Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708. https://doi.org/10.1038/342705a0.

Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37:865-876. https://doi.org/10.1002/humu.23035.

Newman SJ, Mrkonjich L, Walker KK, Rohrbach BW. Canine subcutaneous mast cell tumour: diagnosis and prognosis. J Comp Pathol. 2007;136:231-239. https://doi.org/10.1016/j.jcpa.2007.02.003.

Thompson JJ, Yager JA, Best SJ, et al. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Vet Pathol. 2011;48:169-181. https://doi.org/10.1177/0300985810390716.

Amatya VJ, Naumann U, Weller M, Ohgaki H. TP53 promoter methylation in human gliomas. Acta Neuropathol. 2005;110:178-184. https://doi.org/10.1007/s00401-005-1041-5.

Janostiak R, Vyas M, Cicek AF, Wajapeyee N, Harigopal M. Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation. Exp Mol Pathol. 2018;105:41-49. https://doi.org/10.1016/j.yexmp.2018.05.011.

Dahl C, Abildgaard C, Riber-Hansen R, et al. KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J Invest Dermatol. 2015;135:516-524. https://doi.org/10.1038/jid.2014.372.

Chang S-W, Chao W-R, Ruan A, Wang PH, Lin JC, Han CP. A promising hypothesis of c-KIT methylation/ expression paradox in c-KIT (+) squamous cell carcinoma of uterine cervix-CTCF transcriptional repressor regulates c-KIT proto-oncogene expression. Diagn Pathol. 2015;10:207-203. https://doi.org/10.1186/s13000-015-0438-2.

Mayr B, Resch S, Hepperle S, et al. Comparative studies in the promoter and exon 1 regions of tumour suppressor p53 in several mammalian species: absence of mutations in a panel of spontaneous domestic animal tumours. J Vet Med Ser A. 2000;47:593-597. https://doi.org/10.1046/j.1439-0442.2000.00322.x.

Da Ros S, Zorzan E, Giantin M, et al. Sequencing and G-quadruplex folding of the canine proto-oncogene KIT promoter region: might dog be used as a model for human disease? PLoS One. 2014;9:e103876. https://doi.org/10.1371/journal.pone.0103876.

Alnaes GI, Ronneberg JA, Kristensen VN, Tost J. Heterogeneous DNA methylation patterns in the GSTP1 promoter lead to discordant results between assay technologies and impede its implementation as epigenetic biomarkers in breast cancer. Genes. 2015;6:878-900. https://doi.org/10.3390/genes6030878.

London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999;27:689-697.

Thompson JJ, Morrison JA, Pearl DL, et al. Receptor tyrosine kinase expression profiles in canine cutaneous and subcutaneous mast cell tumors. Vet Pathol. 2016;53:545-558. https://doi.org/10.1177/0300985815610388.

Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg. 2008;37:454-460. https://doi.org/10.1111/j.1532-950X.2008.00407.x.

Koshino A, Goto-Koshino Y, Setoguchi A, et al. Mutation of p53 gene and its correlation with the clinical outcome in dogs with lymphoma. J Vet Intern Med. 2016;30:223-229. https://doi.org/10.1111/jvim.13807.

Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. In: Vande Woude GF, Klein G, eds. Advances in Cancer Research. New York: Academic Press; 1997:141-196.

Yan F, Shen N, Pang J, et al. A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness. Oncogene. 2017;36:6919-6928. https://doi.org/10.1038/onc.2017.305.

Pogribny IP, James SJ. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett. 2002;176:169-174.